Precipio, Inc. (PRPO)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.0600 |
| Open | 1.0500 |
| Bid | 1.1100 x 3100 |
| Ask | 1.1600 x 1100 |
| Day's Range | 1.0500 - 1.1200 |
| 52 Week Range | 0.9100 - 4.1700 |
| Volume | |
| Avg. Volume | 259,421 |
| Market Cap | 25.206M |
| Beta (5Y Monthly) | 2.31 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3570 |
| Earnings Date | Mar 29, 2022 - Apr 04, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.00 |
- GlobeNewswire
Precipio requests that all Stockholders that have not yet voted, proceed to cast their vote
Meeting Adjourned, new meeting set for July 5th at 10am EDTNEW HAVEN, Conn., June 14, 2022 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ:PRPO), announced today that the Company’s 2022 Annual Meeting of Stockholders was adjourned due to the fact that the percentage of stockholders participating in the proxy vote totaled approximately 49%, thereby not reaching the quorum of 50% required to conduct business and approve the measures. The meeting is rescheduled for July 5th
- GlobeNewswire
Keith Meadors Joins Precipio to Lead its Products Division
Seasoned, experienced industry executive with a track record of managing 9-figure revenue sales organizationsNEW HAVEN, Conn., June 13, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company, Precipio, Inc. (NASDAQ: PRPO), today announced that Keith Meadors has joined Precipio as its Senior Vice President of its Products Division, to manage and drive company growth and market share. Keith brings over 30 years of executive experience in various healthcare organizations, including his recen
- GlobeNewswire
Precipio Receives CE-IVD Certification to Market Multiple HemeScreen® Panels in Europe
This Regulatory Approval Opens the Company’s Reach to the European MarketNEW HAVEN, Conn., May 24, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company, Precipio, Inc. (NASDAQ: PRPO), today announced that it has received CE-IVD approval for sale of its HemeScreen® reagents in the European Union. The approval was provided by the Medicines & Healthcare Products Regulatory Agency. The CE-IVD (European Conformity In-Vitro Diagnostic Medical Devices) certification allows Precipio to market t
